leadf
logo-loader
viewCEL-SCI Corporation
(
AMEX:CVM
)

CelSci updates Phase 3 clinical trial of Advanced Head and Neck Cancer treatment

CEL-SCI Corporation (NYSE:CVM) CEO Geert Kersten sat down with Proactive Investors at the ThinkEquity Conference in New York. The Virginia-based biotech treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with its drug Multikine before they receive surgery, radiation and/or chemotherapy.

Quick facts: CEL-SCI Corporation

Follow
AMEX:CVM

Price: 11.23 USD

Market Cap: $483.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Clean Seed Capital Group announces Deerland Equipment as SMART Seeder Max dealer

Clean Seed Capital Group Chief Operating Officer Colin Rush joined Steve Darling from Proactive to share news the company has announced the appointment of Deerland Equipment as a Clean Seed SMART Seeder MAX dealer. Rush telling Proactive Deerland is a multi-store agricultural equipment dealer...

6 minutes ago

2 min read